BG
HTGM

BlackRock Group’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

BlackRock Group’s Portfolio HTGM Stock Details HTGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-560
Closed -$229K – 3009
2016
Q3 		$229K Sell
560
-47
-8% -$21K ﹤0.01% 2587
2016
Q2 		$297K Sell
607
-226
-27% -$115K ﹤0.01% 2442
2016
Q1 		$430K Sell
833
-120
-13% -$67.1K ﹤0.01% 2300
2015
Q4 		$748K Hold
953
– – ﹤0.01% 2045
2015
Q3 		$1.31M Hold
953
– – ﹤0.01% 1732
2015
Q2 		$1.91M Buy
+953
New +$2.43M ﹤0.01% 1583

Other funds holding HTGM

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SIM
Sonora Investment Management Tucson, Arizona $798M AUM 17.61% 1-Year Est. Return
IF
Ironwood Financial Tucson, Arizona $639M AUM 19.03% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BlackRock Group's HTGM Position: Q4 2016 in Review

BlackRock Group sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q4 2016, closing a stake of 560 shares — an estimated $229K sold.

BlackRock Group first reported a position in HTGM in Q2 2015 and held it in 6 quarters. The position peaked at $1.91M in Q2 2015. 13 funds tracked by Wall St. Rank hold HTGM as of Q4 2016.

  • BlackRock Group reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
  • BlackRock Group sold 560 HTG Molecular Diagnostics, Inc. Common Stock shares in Q4 2016, an estimated $229K.
  • BlackRock Group first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q2 2015 and held it in 6 quarters.
  • BlackRock Group's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $1.91M in Q2 2015.
  • 13 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.